文献速递肿瘤 PET/CT

Nectin-4靶向放射性配体[68Ga]Ga-FZNR-1在胰腺导管腺癌中的初步研究:与[18F]-FDG的头对头比较

A pilot study of nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [18F]-FDG.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-24

结果显示两者检测原发灶、淋巴结转移和远处转移的灵敏度相当,[68Ga]Ga-FZNR-1对远处转移特异度和准确度略高;其SUVmax和TBR与Nectin-4表达显著正相关(均r=0.89,均p<0.001)。

要点

  • [68Ga]Ga-FZNR-1与[18F]-FDG检测PDAC原发灶、淋巴结及远处转移灵敏度相当。
  • [68Ga]Ga-FZNR-1对远处转移特异度100.00%、准确度100.00%,略高于[18F]-FDG。
  • [68Ga]Ga-FZNR-1的SUVmax和TBR与Nectin-4表达显著正相关(均r=0.89,均p<0.001)。

核心结论

  • [68Ga]Ga-FZNR-1对PDAC原发、转移和复发灶诊断表现优秀,可能补充[18F]-FDG PET/CT未检出的远处转移。
  • [68Ga]Ga-FZNR-1 PET/CT可量化Nectin-4表达,并可能对PDAC患者预后评估有潜在预测价值。

研究设计与样本

  • 前瞻性初步研究,纳入33例PDAC患者,行头对头[68Ga]Ga-FZNR-1与[18F]-FDG PET/CT用于初始分期或复发转移检测。

主要发现

  • [18F]-FDG与[68Ga]Ga-FZNR-1检测原发肿瘤灵敏度为96.00%(24/25)对92.00%(23/25)。
  • 检测淋巴结转移灵敏度为88.24%(15/17)对82.35%(14/17),检测远处转移均为95.24%(20/21)。
  • [68Ga]Ga-FZNR-1对远处转移特异度为100.00%、准确度为100.00%,[18F]-FDG分别为93.75%和96.97%。
  • ROC曲线显示[68Ga]Ga-FZNR-1检测Nectin-4表达病灶具有高灵敏度和特异度。
  • [68Ga]Ga-FZNR-1的SUVmax和TBR均与Nectin-4表达显著正相关(均r=0.89,均p<0.001)。

临床怎么用

  • 对PDAC初始分期或疑复发转移者,可考虑[68Ga]Ga-FZNR-1 PET/CT与[18F]-FDG PET/CT互补使用。
  • [68Ga]Ga-FZNR-1 PET/CT可用于无创量化肿瘤Nectin-4表达,辅助治疗选择与预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nectin-4 is highly expressed in pancreatic cancer. Accurate and quantitative measurements of Nectin-4 is useful for tumor diagnosis, treatment selection, and prognostic assessment. This study aimed to evaluate the diagnostic efficacy of a Nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 for pancreatic ductal adenocarcinoma. METHODS: Thirty-three patients with PDAC were recruited and underwent head-to-head [68Ga]Ga-FZNR-1 and [18F]-FDG PET/CT for initial staging or to detect recurrence and metastases. PET/CT findings were confirmed by histopathology or follow-up imaging. Thirteen primary and metastatic lesions from the 33 patients were evaluated for Nectin-4 immunohistochemical expression. RESULTS: [18F]-FDG and [68Ga]Ga-FZNR-1 PET/CT were comparable in detecting primary tumors, lymph node metastases, and distant metastases (96.00% [24/25] vs. 92.00% [23/25], 88.24% [15/17] vs. 82.35% [14/17], 95.24% [20/21] vs. 95.24% [20/21]). [68Ga]Ga-FZNR-1 PET/CT demonstrated slightly higher specificity and accuracy than [18F]-FDG PET/CT for distant metastases (100.00% vs. 93.75%, 100.00% vs. 96.97%). The receiver operating characteristic (ROC) curve revealed that [68Ga]Ga-FZNR-1 had high sensitivity and specificity in detecting Nectin-4-expressing lesions. Both SUVmax and TBR on [68Ga]Ga-FZNR-1 PET/CT were significantly and positively correlated with the expression of Nectin-4 (both r = 0.89, both p < 0.001). CONCLUSION: [68Ga]Ga-FZNR-1 is excellent in diagnosing primary, metastatic, and recurrent lesions of PDAC. In particular, it may be a useful complement in patients with distant metastases that cannot be detected by [18F]-FDG PET/CT. [68Ga]Ga-FZNR-1 PET/CT could quantify the Nectin-4 expression. Moreover, [68Ga]Ga-FZNR-1 PET/CT may have potential predictive value in the prognostic assessment of patients with PDAC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jiang C, Wei M, Li P, et al. A pilot study of nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [18F]-FDG. Eur J Nucl Med Mol Imaging. 2025. PMID: 41134323. doi:10.1007/s00259-025-07609-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。